Video navigation menu

• What can be done about the increasing prevalance of diabetes and associated CV disease? 0:15
• Assessing CV benefit of diabetes agents in large CV outcomes trials 2:41
• Targeting the SGLT2 transporter to lower blood glucose exerts various effects 3:24
• Are the EMPA-REG OUTCOMES results reproducible? 7:27
• Where are we now with anti-diabetic treatment in relation to lowering CV risk? 8:36